These are impressive numbers and they mirror the latest jurisdiction regarding CBD from the Court of Justice of the European Union (CJEU) that confidence and professionality are at the heart of this growth. European countries are experiencing transformation in the regulations controlling the marketing of cannabis products.
At ADREXpharma® we strive to lead the way in product innovation and development in order to respond and participate fully in any potential market growth.
ADREXpharma® is the first independent German pharmaceutical company specialising in the development and distribution of medicinal cannabis and also providing a gateway into the European market. Our product portfolio consists not only of a wide range of cannabis flowers and extracts but also compounding products like dronabinol and pharmaceutical Cannabidiol (CBD) as well as innovative CBD-Cosmetic-Products. Due to our unique supply network, ADREXpharma® sets a new benchmark level by serving all of the approximate 19,000 pharmacies in Germany.
Our two collaborations with the German pharma companies, STADA and Neuraxpharm, for the GMP (good manufacturing practice) Full-Service and the distribution of Canadian and Israeli medical cannabis products has expanded our international footprint and has mirrored the tendency in the market for strategic collaborations within Europe and beyond.
We are proud to be one of the few German companies to hold all the necessary licences to operate in the German medical cannabis market. This will accelerate our growth potential even further over the next few years.
At ADREXpharma® we are committed to quality, authenticity and innovation, as well as to contributing to the growing body of evidence-based research regarding the benefits and efficacy of cannabis to validate new therapy options for patients. ADREXpharma® aims to provide the best possible treatment for medical cannabis patients – today and always.
Founder ADREXpharma® GmbH
The European Cannabis Report: 6th Edition takes a deep dive on the current social, economic, regulatory and health trends. The report also includes sales forecasts of medical and adult-use cannabis in the US and Canada.